Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo

Molecular Pharmacology

Volumn 62, Issue 3, 2002, Pages 497-506

  Tilley, Douglas G ^a   Maurice, Donald H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; BUCLADESINE; CILOSTAMIDE; CYCLIC AMP; CYCLOHEXIMIDE; DACTINOMYCIN; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; PHENYLEPHRINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG; ZARDAVERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; FEMORAL ARTERY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; AORTA; BUCLADESINE; CYCLIC AMP; FEMORAL ARTERY; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR;

EID: 0036765832     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.3.497     Document Type: Article

References (39)

1. Baillie G, MacKenzie SJ, and Houslay MD (2001) Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 60:1109-1111.
2. Beard MB, O'Connell JC, Bolger GB, and Houslay MD (1999) The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett 460:173-177.
3. Choi YH, Elholm D, Krall J, Ahmad F, Degerman E, Manganiello VC, and Movsesian MA (2001) Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353:41-50.
4. Conti M and Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38.
5. Davis CW and Daly JW (1979) A simple direct assay of 3′, 5′-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-boronate affinity gel chromatography. J Cyclic Nucleotide Res 5:65-74.
6. Degerman E, Belfrage P, and Manganiello VC (1997) Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826.
7. Dunkerley HA, Tilley DG, Palmer D, Liu H, Jimmo SL, and Maurice DH (2002) Reduced phosphodiesterase 3 activity and phosphodiesterase 3A levels in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol Pharmacol 61:1033-1040.
8. Grange M, Sette C, Cuomo M, Conti M, Legarde M, Prigent AF, and Nemoz G (2000) The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site. J Biol Chem 275:33379-33387.
9. Haslam RJ, Dickinson NT, and Jang EK (1999) Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost 82:412-423.
10. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, and Houslay MD (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO (Eur Mol Biol Organ) J 18:893-903.
11. Houslay MD (1998) Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. Semin Cell Dev Biol 9:161-167.
12. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, et al. (1997) Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med 3:779-779.
13. Kasuya J, Liang SJ, Goko H, Park SH, Kato K, Xu ZD, Hockman S, Manganiello VC, and Fujita-Yamaguchi Y (2000) Cardiac type cGMP-inhibited phosphodiesterase (PDE3A) gene structure: similarity and difference to adipocyte type PDE3B gene. Biochem Biophys Res Commun 268:827-834.
14. Kostic MM, Erdogan S, Rena G, Borchert G, Hoch B, Bartel S, Scotland G, Huston E, Houslay MD, and Krause EG (1997) Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol 29:3135-3146.
15. Koyama H, Bornfeldt KE, Fukumoto S, and Nishizawa Y (2001) Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186:1-10.
16. Liu H and Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501-1510.
17. Liu H and Maurice DH (1999) Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J Biol Chem 274:10557-10565.
18. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC and Maurice DH (2000) Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 275:26615-26624.
19. 2-terminal UCR regions. J Biol Chem 275:16609-16617.
20. Maeda H, Ozawa H, Saito T, Irie T, and Takahata N (1997) Potential antidepressant properties of forskolin and a novel water-soluble forskolin (NKH477) in the forced swimming test. Life Sci 61:2435-2442.
21. Manganiello VC and Degerman E (1999) Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb Haemostasis 2:407-411.
22. Maurice DH and Haslam RJ (1990a) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenyl cylcase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671-681.
23. Maurice DH and Haslam RJ (1990b) Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol 191:471-475.
24. McPhee I, Yarwood SJ, Scotland G, Huston E, Beard MB, Rose AH, Houslay ES and Houslay MD (1999) Association with the SRC family tyrosy kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J Biol Chem 274: 11796-11810.
25. 2 involved in the desensitization of β-mimetics in late pregnancy human myometrium? J Clin Endocrinol Metab 86:5958-5365.
26. Miki T, Taira M, Hockman S, Shimada F, Lieman J, Napolitano M, Ward D, Taira M, Makino H and Manganiello VC (1996) Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics 36:476-485.
27. Movsesian MA 1999 Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. J Am Coll Cardiol 34:318-324.
28. Owens GK (1996) Molecular control of vascular smooth muscle cell differentiation. Acta Physiol Scand 164:623-635.
29. Palmer D and Maurice DH (2000) Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase inhibition in human cardiovascular tissues. Mol Pharmacol 58:247-252.
30. Palmer WK and Doukas S (1984) Dibutyryl cyclic AMP increases phosphodiesterase activity in the rat heart. Can J Physiol Pharmacol 62:1225-1230.
31. Polson JB and Strada SJ (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36:403-427.
32. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, and Bondy CA (1995) Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest 95:1528-1538.
33. Rose RJ, Liu H, Palmer D, and Maurice DH (1997) Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol 122:233-240.
34. Rybalkin SD and Bornfeldt KE (1999) Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemostasis 82:424-434.
35. Soderling SH and Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
36. Thyberg J (1998) Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Histol Histopathol 13:871-891.
37. Tümer N, Bowman CJ, LaRochelle JS, Kelley A, and Scarpae PJ (1997) Induction of tyrosine hydroxylase by forskolin: modulation with age. Eur J Pharmacol 324:57-62.
38. 2+ current in rat ventricular myocytes. Br J Pharmacol 127:65-74.
39. Yarwood SJ, Steele MR, Scotland G, Houslay MD, and Bolger GB (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274:14909-14917.